← All trials
NCT05388448
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 21, 2022
- Primary completion
- Sep 1, 2023
- Completion date
- Dec 1, 2023
- First posted
- May 24, 2022
- Last posted
- May 24, 2022
- Enrollment
- 105
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TASK Applied ScienceLead sponsor
- GlaxoSmithKlineCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.